- A new oral delivery system for 5-ASA: preliminary clinical findings for MMxCosimo Prantera
Department of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
Inflamm Bowel Dis 11:421-7. 2005..This study had 2 objectives: (1) to evaluate the therapeutic response to MMx in patients with active left-sided disease and (2) to gain additional insights as to how the therapy would compare with topical 5-ASA...
- Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trialCosimo Prantera
Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
Dig Liver Dis 43:459-64. 2011..Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects...
- Budesonide multi-matrix system formulation for treating ulcerative colitisCosimo Prantera
Gastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87 00152 Rome, Italy 39 6 3202643 39 6 3202643
Expert Opin Pharmacother 15:741-3. 2014..Therefore, the effective dosage should be 9 mg also in maintenance, but not for > 4 - 6 months, because a prolonged treatment has showed to increase the rate of side effects. ..
- Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's diseaseCosimo Prantera
Gastroenterology Unit, San Camillo Forlanini Hospital, Rome, Italy
Gastroenterology 142:473-481.e4. 2012..We performed a clinical phase 2 trial to determine whether a gastroresistant formulation of rifaximin (extended intestinal release [EIR]) induced remission in patients with moderately active CD...
- Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with AsacolC Prantera
Department of Gastroenterology, Azienda Osp S Camillo Forlanini, Rome, Italy
Aliment Pharmacol Ther 30:908-18. 2009..5-ASA-MMX (1.2 g/tablet) is a 5-aminosalicylic acid formulation, designed for once-daily dosing in the treatment of ulcerative colitis...
- Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GGC Prantera
Division of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
Gut 51:405-9. 2002..The aim of this randomised placebo controlled study was to determine if Lactobacillus GG, given by mouth for one year, could prevent Crohn's recurrent lesions after surgery or to reduce their severity...
- Mycobacteria and Crohn's disease: the endless storyC Prantera
Gastrointestinal Unit, San Camillo Forlanini Hospital, Rome, Italy
Dig Liver Dis 39:452-4. 2007
- Probiotics for Crohn's disease: what have we learned?C Prantera
Division of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, 00149 Roma, Italia
Gut 55:757-9. 2006
- Probiotics and Crohn's diseaseC Prantera
Division of Gastroenterology, S Camillo Forlanini Hospital, Rome, Italy
Dig Liver Dis 34:S66-7. 2002..Forty-five patients have been randomised to receive Lactobacillus rhamnosus strain GG or placebo for 12 months. The results have shown no differences in endoscopic and clinical remission between the two groups...
- Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximinC Prantera
Operative Unit of Gastroenterology, St Camillo Forlanini Hospital, Rome, Italy
Aliment Pharmacol Ther 23:1117-25. 2006..Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients...
- Antibiotics and probiotics in inflammatory bowel disease: why, when, and howCosimo Prantera
Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
Curr Opin Gastroenterol 25:329-33. 2009..To summarize recent evidence on the role of intestinal bacteria in inflammatory bowel diseases, and of antibiotics and probiotics in their treatment. The implications connected with the use of antibiotics are also examined...
- Use of antibiotics in the treatment of Crohn's diseaseMaria Lia Scribano
Gastroenterology Operative Unit, Azienda Ospedaliera San Camillo Forlanini, 00152 Rome, Italy
World J Gastroenterol 19:648-53. 2013..Rifaximin, characterized by an excellent safety profile, has provided promising results in inducing remission of CD...
- Delayed-release Multi Matrix System (MMX) mesalazine in ulcerative colitis: a viewpoint by Cosimo PranteraCosimo Prantera
Gastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
Drugs 67:2643-4. 2007
- Antibiotics and inflammatory bowel diseasesMaria Lia Scribano
Gastroenterology Operative Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
Dig Dis 31:379-84. 2013..Since their long-term use is frequently complicated by a high rate of side effects, the use of antibiotics that work locally appears to be promising...
- Rifaximin and Crohn's diseaseCosimo Prantera
Cosimo Prantera, Maria Lia Scribano, Gastroenterology Operative Unit, Azienda Ospedaliera San Camillo Forlanini, 00152 Rome, Italy
World J Gastroenterol 19:7487-8. 2013..We also analyze the role of rifaximin against gut bacteria and the clinical situations that could obtain the best results from antibiotics. ..
- Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activityCosimo Prantera
Azienda Ospedaliera San Camillo Forlanini, via Monterosi 116, 00191 Rome, Italy
Therap Adv Gastroenterol 6:137-56. 2013..While the tolerability of these glucocorticosteroids is favourable, more research comparing these new agents with traditional systemic glucocorticosteroids is warranted...
- Does stapled functional end-to-end anastomosis affect recurrence of Crohn's disease after ileocolonic resection?Roberto Tersigni
Department of Surgical Sciences, General Surgery 1, San Camillo Hospital, Rome, Italy
Hepatogastroenterology 50:1422-5. 2003..The influence of anastomotic configuration on the incidence of reoperation was evaluated in patients undergoing resection for Crohn's disease...
- Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate useSilvio Danese
Inflamm Bowel Dis 14:1168-70. 2008